For the second year in a row, the Children’s Tumor Foundation will be among a small group of foundations invited to speak at the Biotechnology Industry Organization CEO and Investors Conference to be held Feb 14-15 in New York. The BIO conference is a forum for emerging biotechs to meet investors and form partnerships with larger pharmas; for CTF, it is a valuable opportunity to present the pipeline of candidate neurofibromatosis drugs currently in preclinical testing and clinical trials, and to engage new industry partners who have drugs that could be future neurofibromatosis treatments. CTF Chief Scientific Officer Dr. Kim Hunter-Schaedle will present at 3pm on February 14th. This terrific opportunity builds on CTF’s recent invited presentation at the Milken Institute’s Partnering for Cures conference which can be viewed here.
CTF to Present Neurofibromatosis Pipeline at 2011 BIO Investor Conference
